Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation

Montague, T. S.; Murphy, Barbara

doi:10.1016/j.ecl.2008.11.004

Cited by 8 publications

(2 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High concentration of serum UA may lead to nephropathy and renal function impairment by directly mechanical damage or indirectly inflammation and cell phenotype inversion, resulting in the reduction of UA excretion and forming a vicious cycle. Normal ranges of Hb and Alb were also reported beneficial to stable internal environment and normal physiological activities [14, 15]. Theories above could provide our result with support that serum UA and Hb levels during the follow-up can significantly affect the progress of IgAN to ESRD.…”

Section: Discussionsupporting

confidence: 76%

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

Shu

Zhang

et al. 2017

BMC Nephrol

View full text Add to dashboard Cite

BackgroundThere were few related studies aiming to severe IgA nephropathy (IgAN) which could progress rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and promising precautions is essential.MethodsA single center case–control study was performed. Fifty ESRD patients with the primary cause of IgAN and a short renal survival time of less than ten years after diagnose were enrolled in the case group. One hundred IgAN patients with a renal survival time of more than ten years were enrolled in the control group. IgA Oxford classification scores, clinical data at baseline and during the follow-up were collected. Multivariate logistic regression was used to investigate factors associated with the development of ESRD.ResultsThere were significant differences in baseline clinical data between these two groups, as well as the constituent ratio of Oxford MEST-score. Distinct differences were observed in time-average uric acid(TA-UA), time-average hemoglobin(TA-Hb), time-average albumin(TA-Alb), time-average total cholesterol(TA-TC) and time-average urinary protein(TA-P) during the follow-up. In multivariate logistic models, IgA Oxford score M1(OR = 5.10, P = 0.018) and eGFR(OR = 0.97, P = 0.039) at biopsy, TA-UA (OR = 2.06, P = 0.026) and TA-Hb (OR = 0.53, P = 0.022) during the follow-up were identified independent factors for developing ESRD.ConclusionIgAN patients with pathological assessment of M1, low baseline eGFR, TA-Hb and high TA-UA were more likely to progress to ESRD, and should be paid more attention. Appropriate regulations of UA, Hb and urine protein after diagnose may be a promising treatment.Electronic supplementary materialThe online version of this article (doi:10.1186/s12882-016-0429-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 76%

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

Shu

Zhang

et al. 2017

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Cardiovascular disease (CVD) is now the primary cause of patient death following renal transplantation and accounts for a third of all graft losses [3]. Typical clinical risk factors for post‐transplant CVD contribute to morbidity and mortality and current clinical practice guidelines to prevent these modifiable factors are well‐recognized [8,9]. In terms of dyslipidemia, current practice guidelines focus principally on using statin therapy to control low‐density lipoprotein (LDL) levels [10,11].…”

Section: Introductionmentioning

confidence: 99%

Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients

Barn

Laftavi

Pierce

et al. 2009

Transplant International

View full text Add to dashboard Cite

Summary Long‐term kidney transplant graft and patient survival is often limited by cardiovascular (CV) disease. Risk factors for CV disease such as diabetes, hypertension and elevated low‐density lipoprotein levels are well documented; however, the impact of low levels of high‐density lipoprotein (HDL) has not been defined. We performed a retrospective chart review of 324 consecutive renal transplant recipients from 2001 to 2007 to correlate baseline HDL levels with major adverse cardiovascular events (MACEs) defined as a composite of new onset CV illness, cerebral vascular events and peripheral vascular disease. A total of 92 MACEs occurred over a total of 1913 patient years of follow‐up. Low HDL cholesterol levels were noted in 58.3% of patients. Compared with those with normal HDL levels, a greater percentage of patients with low HDL levels had post‐transplant MACEs (20% vs. 60% respectively) and experienced an increased rate of all cause mortality. Sixty‐two percent of all MACEs occurred in patients with low HDL levels. In the low HDL group, the odds ratio for experiencing a MACE was 1.92. Therefore, HDL cholesterol may provide an important new therapeutic target to prevent vascular morbidity and mortality following renal transplantation.

show abstract

Glycemic Control and Cardiorenal Outcomes in Patients With Advanced Chronic Kidney Disease: Relative or Absolute Risks?

Goff¹

2011

Arch Intern Med

View full text Add to dashboard Cite

show abstract

Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation

Cited by 8 publications

References 75 publications

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients

Glycemic Control and Cardiorenal Outcomes in Patients With Advanced Chronic Kidney Disease: Relative or Absolute Risks?

Contact Info

Product

Resources

About